Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166206 | 0.85 | CA1 (0.42) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL6612741 | 0.84 | TDP1 (0.44) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL10435327 | 0.83 | TDP1 (0.39) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL6611508 | 0.82 | CTSK (0.41) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL571467 | 0.81 | CTSK (0.40) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL16061377 | 0.81 | CTSK (0.40) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL6609512 | 0.81 | CA12 (0.42) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL20159624 | 0.81 | CTSK (0.40) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL4018044 | 0.81 | MEN1 (0.40) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL10744068 | 0.81 | CTSK (0.40) | CA1CA7CA12CA14TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114276411-A | Solid phase synthesis method of cyclic peptide compound containing trithioether bond | 北京大学深圳研究生院 | 2022-04-05 | — | — | CN | claimed |
| CN-113874375-A | Cyclic amide compounds and methods thereof for the treatment of rabies | 株式会社大分大学先端医学研究所 | 2021-12-31 | — | — | CN | claimed |
| WO-2020246503-A1 | CYCLIC AMIDE COMPOUNDS FOR RABIES TREATMENT AND METHOD THEREOF | 株式会社大分大学先端医学研究所 | 2020-12-10 | — | — | WO | claimed |
| CN-111757880-A | Method for synthesizing cyclic depsipeptides | 拜耳动物保健有限责任公司 | 2020-10-09 | — | — | CN | claimed |
| EP-3676265-A1 | METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES | Bayer Animal Health GmbH (DE) | 2020-07-08 | — | — | EP | claimed |
| US-8778956-B2 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | claimed |
| EP-1601674-B1 | Hydroxyalkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-08 | — | — | EP | claimed |
| JP-4712384-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| US-7582649-B2 | Oral administration of a dosage of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one and a carrier; opiod receptor-like-1 G-protein coupled receptor inhibitors; psychological disorders; nervous system disorders; antidiabetic agents | JANSSEN PHARMACEUTICA, NV (BE) | 2009-09-01 | — | — | US | claimed |
| US-20090124614-A1 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | BATTISTA KATHLEEN | 2009-05-14 | — | — | US | claimed |
| CN-1343206-A | Cyclocompound | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-04-03 | — | — | CN | claimed |
| WO-2001098278-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-12-27 | — | — | WO | claimed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | claimed |
| WO-2001030768-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-05-03 | — | — | WO | claimed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | claimed |
| US-5856324-A | Use of dioxomorpholines for combat endoparasites, dioxomorpholines and process for their production | BAYER AKTIENGESELLSCHAFT (DE) | 1999-01-05 | — | — | US | claimed |
| US-5571793-A | COMBATTING ENDOPARASITES IN HUMANS OR ANIMALS BY ADMINISTERING PEPTIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-05 | — | — | US | claimed |
| EP-0007470-B1 | CEPHEM COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-10-12 | — | — | EP | claimed |
| US-4268509-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-19 | — | — | US | claimed |
| EP-0007470-A2 | Cephem compounds, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-02-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124614-A1 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | OPRL1, ADRA1D, OPRD1 | CA1 3536/4885CA7 4234/4885CA12 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.